Analysis of the correlation between adiponectin gene polymorphism and metabolic syndrome incidence and its relationship with the degree of atherosclerosis in patients

The aim of the present study was to determine the correlation between adiponectin (APN) gene polymorphism, metabolic syndrome incidence, and degree of atherosclerosis in patients with this disease. The study was conducted on 369 unrelated patients, diagnosed with metabolic abnormalities. The patients were divided into the metabolic syndrome group (MS group, n=182), the metabolic abnormality group (n=187) and the control group with metabolic normality (n=134), as per the degree of metabolic abnormality. The gene polymorphism of rs121917815 site of APN gene was detected by TaqMAN probe technique, and the OR values of different genotypes and alleles were calculated. The APN protein, C-reactive protein (CRP), IL-1 and high-density lipoprotein (HDL) 2a and 2b expression level changes were detected by immunoblotting. The atherosclerosis index (AI) of each allele in patients with MS was calculated. Compared with the control group, the expression levels of APN protein in the metabolic abnormality and MS groups were significantly decreased. However, there was no distinct difference in the comparison of gene polymorphism between the control and metabolic abnormality groups. The CC genotype frequency and C allele frequency of rs121917815 polymorphic site in the MS group were significantly increased, compared with the control group. The TT genotype frequency and T allele frequency were significantly decreased and the OR values of the CC genotype and C allele were increased. The results of immunoblotting showed that there was no obvious change of CRP, IL-1, HDL-2a and HDL-2b in the three groups, and there was no statistically significant difference in the comparison of AI between the MS and control groups as well as the metabolic abnormality group. The APN gene polymorphic site rs121917815 is associated with MS. The occurrence of CC genotype and C allele increased the incidence of MS, but it did not increase the degree of atherosclerosis in MS patients.